{"nctId":"NCT00563368","briefTitle":"A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults","startDateStruct":{"date":"2007-12"},"conditions":["Obesity"],"count":756,"armGroups":[{"label":"VI-0521 Top","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"VI-0521 Mid","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"TPM 46","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: topiramate"]},{"label":"TPM 92","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: topiramate"]},{"label":"PHEN 7.5","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: phentermine"]},{"label":"PHEN 15","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: phentermine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: VI-0521"]}],"interventions":[{"name":"VI-0521","otherNames":[]},{"name":"VI-0521","otherNames":[]},{"name":"topiramate","otherNames":[]},{"name":"topiramate","otherNames":[]},{"name":"phentermine","otherNames":[]},{"name":"phentermine","otherNames":[]},{"name":"VI-0521","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 70 years of age or less with body mass index (BMI) between 30 and 45 kg/m2\n* Informed Consent\n* Females of child-bearing potential must be using adequate contraception\n\nExclusion Criteria:\n\n* Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months\n* Clinically significant renal, hepatic or psychiatric disease\n* Unstable thyroid disease or replacement therapy\n* Nephrolithiasis\n* Obesity of known genetic or endocrine origin\n* Participation in a formal weight loss program or lifestyle intervention\n* Glaucoma or elevated intraocular pressure\n* Pregnancy or breastfeeding\n* Drug or Alcohol abuse\n* Smoking cessation within previous 3 months or plans to quit smoking during study\n* Eating disorders within past year\n* Cholelithiasis within past 6 months\n* Type 2 diabetes\n* Previous bariatric surgery\n* Bipolar disorder or psychosis\n* Steroid hormone therapy not stable for 3 months\n* Systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Weight Loss From Baseline to Week 28","description":"Percent weight loss from baseline to Week 28 with last observation carried forward (LOCF)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.61"},{"groupId":"OG001","value":"5.5","spread":"0.61"},{"groupId":"OG002","value":"5.1","spread":"0.61"},{"groupId":"OG003","value":"8.5","spread":"0.62"},{"groupId":"OG004","value":"6.1","spread":"0.61"},{"groupId":"OG005","value":"6.4","spread":"0.62"},{"groupId":"OG006","value":"9.2","spread":"0.61"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"43.3","spread":null},{"groupId":"OG002","value":"39.2","spread":null},{"groupId":"OG003","value":"62.1","spread":null},{"groupId":"OG004","value":"46.2","spread":null},{"groupId":"OG005","value":"48.6","spread":null},{"groupId":"OG006","value":"66.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["Headache","Paresthesia","Upper Respiratory Tract Infection","Dry Mouth","Nasopharyngitis"]}}}